海洋之心 - 心衰

Inhibiting RhoA Activation Via GDP-State Stabilization to Relieve Heart Failure.

Fri, 20 Mar 2026 00:00:00 +0800

Given the persistently high morbidity and mortality of heart failure (HF), targeting myocardial remodeling, particularly pathological hypertrophy and fibrosis, has become a major therapeutic priority. RhoA (Ras homolog gene family member A), a small GTPase governing cytoskeletal reorganization and c

Phosphoinositide Depletion and Compensatory Phospho-Signaling in Angiotensin II-Induced Heart Disease: Protection Through PTEN Inhibition.

Fri, 20 Mar 2026 00:00:00 +0800

Contractile dysfunction, hypertrophy, and cell death during heart failure are linked to altered Ca Mice received 1-week infusions of AngII, bisperoxovanadium 1,10 phenanthroline, both, or saline via osmotic minipumps. We used mass spectrometry, super-resolution microscopy, electrophysiology, confoca

Pancreatic Involvement During Acute Heart Failure: Insights from the AVANTI trial.

Fri, 20 Mar 2026 00:00:00 +0800

暂无摘要

Suppressor of variegation 3-9 homolog 1 deficiency attenuates cardiac fibrosis and rescues heart failure through TACC2.

Fri, 20 Mar 2026 00:00:00 +0800

Aberrant and excessive cardiac fibrosis contributes to heart failure. Resident cardiac fibroblasts are the primary source of myofibroblasts that produce extracellular matrix proteins to mediate cardiac fibrosis. Previous studies have implicated suppressor of variegation 3-9 homolog 1 (Suv39h1), a ly

ESKD, Major Cardiovascular Events, and Death Associated With Systemic Inflammation

Tue, 17 Feb 2026 00:00:00 +0800

全身炎症可能在慢性肾病的进展和主要心血管事件（MACE）的发展中发挥作用，但这种效应是否独立于传统心血管危险因素尚不清楚。本研究评估了炎症标志物与终末期肾病（ESKD）患者主要心血管事件和死亡之间的关系。研究纳入了接受透析治疗的ESKD患者，测量了多种炎症标志物（包括C反应蛋白、白细胞介素-6等），并进行了长期随访。主要终点为主要心血管事件（定义为心血管死亡、非致死性心肌梗死和非致死性卒中的复合终点）和全因死亡。结果显示，升高的全身炎症标志物与MACE风险和全因死亡率独立相关，即使在校正传统心血管危险因素后仍然显著。炎症标志物升高的患者发生动脉粥样硬化性心血管事件的风险更高。研究结果表明，全身

Management of dyslipidaemia in patients with comorbidities - facing the challenge: Heart failure.

Thu, 01 Jan 2026 00:00:00 +0800

The combined prevalence of heart failure (HF) with coronary atherosclerosis is frequent and often causally linked. The aim of this review is to elucidate whether lipid lowering drugs (LLDs) are useful in this context. The role of LLDs is interesting in two ways: incidence of HF patients treated with

CAMK2D causes heart failure in mice with RBM20 cardiomyopathy.

Thu, 01 Jan 2026 00:00:00 +0800

Although heart disease arises from different etiologies, treatment remains largely one-size-fits-all, leaving many patients without optimal benefit, which highlights the need for cause-directed therapies. Pathogenic variants in RBM20, a cardiac splicing factor, lead to an aggressive form of dilated

Cancer and heart failure: prevalence, incidence, and prognosis in Scotland.

Thu, 01 Jan 2026 00:00:00 +0800

Many patients with cancer develop heart failure (HF), and many patients with HF develop cancer. Inter-relationships between their natural histories are rarely reported. Health records were obtained for a Scottish region. People aged >50 years were classified by the presence or absence of HF, loop di

Inhibition of the PD-1 immune checkpoint and the development of heart failure in the presence of prior cardiac ischemia.

Thu, 01 Jan 2026 00:00:00 +0800

Immune checkpoint inhibitors (ICI) have revolutionized cancer treatment. However, their use often leads to cardiovascular adverse effects, including cardiac dysfunction. Here, we hypothesized that a prior cardiac ischemic injury could exacerbate cardiac dysfunction due to anti-PD-1 treatment. Furthe

Balancing Clinical and Ethical Considerations Related to Placebo Use in Trials of Incretin-Based Therapies in Heart Failure.

Thu, 01 Jan 2026 00:00:00 +0800

Recent trials have shown that glucagon-like peptide 1 receptor agonists (GLP-1 RAs) and dual gastric inhibitory polypeptide/GLP-1 RAs improve symptoms and functional capacity in patients with heart failure (HF) with preserved ejection fraction and obesity, with or without type 2 diabetes. These stud

Body Mass Index, Clinical Outcomes, and Mortality in Heart Failure: A Mendelian Randomization Study.

Thu, 01 Jan 2026 00:00:00 +0800

Excess adiposity, most commonly indexed through body mass index (BMI), is strongly associated with the development of heart failure (HF). Weight loss therapies improve outcomes in patients with obesity and HF with preserved left ventricular ejection fraction (LVEF), but their effects in HF with redu

Outcomes of Cardiac Resynchronization Therapy in Adults with Congenital Heart Disease and Heart Failure with Reduced Ejection Fraction.

Thu, 01 Jan 2026 00:00:00 +0800

There are limited data about the role of cardiac resynchronization therapy (CRT) in adults with congenital heart disease (CHD) and heart failure with reduced ejection fraction (HFrEF). (i) Assess the relationship between CRT and clinical outcomes (all-cause mortality and cardiovascular events). (ii)

Kidney Disease and Heart Failure: Recent Advances and Current Challenges: Conclusions From a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.

Thu, 01 Jan 2026 00:00:00 +0800

Heart failure (HF) and chronic kidney disease (CKD) frequently coexist, which elevates the risks of hospitalization, disease progression, and death. Despite advances in treating each condition independently, many challenges remain in diagnosing and managing them in combination. In March 2024, Kidney

Using Days Alive and Out of Hospital as the Study Endpoint in Cardiovascular Heart Failure Clinical Trials.

Thu, 01 Jan 2026 00:00:00 +0800

Socioeconomic Correlates of Incident Heart Failure and Consequent Mortality: The All of Us Program.

Thu, 01 Jan 2026 00:00:00 +0800

Although socioeconomic status (SES) is a known determinant of cardiovascular disease, the independent risks of incident heart failure (HF) and consequent mortality portended by individual and neighborhood measures of SES remain less established. This study sought to evaluate the prospective associat

Excess and Dysfunctional Fat as a Primary Driver of Heart Failure With Preserved Ejection Fraction: From Institutional Recognition to Clinical Integration.

Thu, 01 Jan 2026 00:00:00 +0800

Epidemiological and Mendelian randomization studies demonstrate a strong link between central obesity, visceral adiposity, and heart failure with preserved ejection fraction (HFpEF). The AHA (American Heart Association) has specifically identified excess and dysfunctional fat as the primary upstream

Interchangeability of the KCCQ-12 and KCCQ-23 Across >18,000 Participants Enrolled in 4 Large-Scale Trials of Heart Failure.

Thu, 01 Jan 2026 00:00:00 +0800

The 23-item Kansas City Cardiomyopathy Questionnaire (KCCQ-23) is formally qualified by the Food and Drug Administration as a valid patient-reported outcome measure for use in heart failure (HF) clinical trials. However, its length may increase respondent burden. The 12-item version (KCCQ-12) provid

Multi-Organ Physiologic Deficits During Exercise Identify Clinical and Molecular Predisposition to Heart Failure with Preserved Ejection Fraction.

Thu, 01 Jan 2026 00:00:00 +0800

Exercise unmasks limitations in multi-organ system reserve capacity characteristic of heart failure with preserved ejection fraction (HFpEF). However, the metabolic and genetic underpinnings of exercise deficits, and their cumulative contribution to HFpEF severity and prognosis, remain incompletely

Exercise performance in patients with heart failure and impaired iron transport: a single-centre retrospective study.